Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Summit Therapeu ADR (SMMT)

Summit Therapeu ADR (SMMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Summit Therapeu ADR 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131 USA

www.smmttx.com Employees: 159 P: 305-203-2034

Sector:

Medical

Description:

Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.

Key Statistics

Overview:

Market Capitalization, $K 13,610,798
Enterprise Value, $K 13,505,608
Shares Outstanding, K 771,150
Float, K 116,444
% Float 15.10%
Short Interest, K 35,754
Short Float 4.64%
Days to Cover 13.30
Short Volume Ratio 0.68
% of Insider Shareholders 84.90%
% of Institutional Shareholders 4.61%
Annual Net Income, $ -221,320 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -231,790 K
EBIT, $ -935,110 K
EBITDA, $ -935,020 K
3-Year Return 293.39%
5-Year Return 208.94%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.31 on 10/20/25
Next Earnings Date 02/23/26
Earnings Per Share ttm -1.24
EPS Growth vs. Prev Qtr 59.21%
EPS Growth vs. Prev Year -287.50%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

SMMT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -311.15%
Return-on-Assets % -262.35%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 67.42
Book Value/Share 0.26
Interest Coverage -24.47
60-Month Beta -1.51
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar